Biopharmaceutical CMO Market Size & Share

1. The global biopharmaceutical Contract Manufacturing Organization (CMO) market is projected to grow from $19.00 billion in 2025 to $51.61 billion by 2032, with a compound annual growth rate of 15.3%. Key findings from the market analysis:  North America dominates with 39.58% market share in 2024, driven by extensive manufacturing facilities and expanding capabilities  Manufacturing services segment leads the market, supported by increasing contract projects and new facility establishments  Major players include Lonza, WuXi Biologics, Samsung Biologics, and Catalent Inc. Recent significant developments:  Fujifilm Diosynth Biotechnologies signed a manufacturing agreement with TG Therapeutics for BRIUMVI in November 2024  Samsung Biologics implemented an AI-powered integrated biomanufacturing platform in 2022  AGC Biologics received FDA approval for commercial manufacturing at its Milan Cell and Gene Center in December 2024 Market drivers include:  Rising demand for biologics and biosimilars  Cost reduction through outsourcing  Growth in personalized medicine  Adoption of single-use bioprocessing technologies Key challenges facing the industry include high operational costs, strict regulatory requirements, supply chain vulnerabilities, and skilled workforce shortages. Report- Fortune Business Insights - Biopharmaceutical CMO Market Size, Growth & Report [2032] https://www.fortunebusinessinsights.com/biopharmaceutical-cmo-market-103346